HYPER-trial Hyperemic mYocardial Perfusion by adEnosine at diffeRent doses

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2023-505248-20-00

Enrollment

180

Registered

2024-03-05

Start date

2024-10-14

Completion date

Unknown

Last updated

2024-03-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic coronary syndrome

Brief summary

The primary endpoint, myocardial hyperemia, is assessed by quantitative myocardial perfusion CMR imaging (ml/min/g).

Interventions

DRUGClariscan 0

DRUG5 mmol/ ml injektionsvätska

DRUGlösning

DRUGAdenosin Life Medical 5 mg/ml

DRUGInjektions-/infusionsvätska

DRUGlösning.

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
The primary endpoint, myocardial hyperemia, is assessed by quantitative myocardial perfusion CMR imaging (ml/min/g).	—

Countries

Sweden

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026